Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $1.94 billion. The enterprise value is $1.64 billion.
| Market Cap | 1.94B |
| Enterprise Value | 1.64B |
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 142.53 million shares outstanding. The number of shares has increased by 21.68% in one year.
| Current Share Class | 142.53M |
| Shares Outstanding | 142.53M |
| Shares Change (YoY) | +21.68% |
| Shares Change (QoQ) | -1.28% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 92.87% |
| Float | 118.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.41 |
| P/TBV Ratio | 6.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.86, with a Debt / Equity ratio of 0.00.
| Current Ratio | 38.86 |
| Quick Ratio | 38.28 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.67% and return on invested capital (ROIC) is -17.75%.
| Return on Equity (ROE) | -24.67% |
| Return on Assets (ROA) | -17.18% |
| Return on Invested Capital (ROIC) | -17.75% |
| Return on Capital Employed (ROCE) | -23.15% |
| Weighted Average Cost of Capital (WACC) | 10.44% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.79M |
| Employee Count | 34 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -75,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.56% in the last 52 weeks. The beta is 1.13, so TRVI's price volatility has been higher than the market average.
| Beta (5Y) | 1.13 |
| 52-Week Price Change | +12.56% |
| 50-Day Moving Average | 14.10 |
| 200-Day Moving Average | 14.51 |
| Relative Strength Index (RSI) | 48.21 |
| Average Volume (20 Days) | 1,702,979 |
Short Selling Information
The latest short interest is 16.01 million, so 11.23% of the outstanding shares have been sold short.
| Short Interest | 16.01M |
| Short Previous Month | 14.64M |
| Short % of Shares Out | 11.23% |
| Short % of Float | 13.52% |
| Short Ratio (days to cover) | 5.94 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -70.13M |
| Pretax Income | -60.83M |
| Net Income | -60.76M |
| EBITDA | -69.99M |
| EBIT | -70.13M |
| Earnings Per Share (EPS) | -$0.40 |
Balance Sheet
The company has $299.41 million in cash and $527,000 in debt, with a net cash position of $298.88 million or $2.10 per share.
| Cash & Cash Equivalents | 299.41M |
| Total Debt | 527,000 |
| Net Cash | 298.88M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 302.76M |
| Book Value Per Share | 2.12 |
| Working Capital | 297.93M |
Cash Flow
In the last 12 months, operating cash flow was -$61.44 million and capital expenditures -$251,000, giving a free cash flow of -$61.69 million.
| Operating Cash Flow | -61.44M |
| Capital Expenditures | -251,000 |
| Depreciation & Amortization | 140,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -61.69M |
| FCF Per Share | -$0.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.68% |
| Shareholder Yield | -21.68% |
| Earnings Yield | -2.94% |
| FCF Yield | -3.18% |
Analyst Forecast
The average price target for TRVI is $28.18, which is 106.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.18 |
| Price Target Difference | 106.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |